HomeCompareTDAX vs MRK

TDAX vs MRK: Dividend Comparison 2026

TDAX yields 5.15% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $28.7K in total portfolio value· pulled ahead in Year 2
10 years
TDAX
TDAX
● Live price
5.15%
Share price
$20.38
Annual div
$1.05
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$28.1K
Annual income
$715.72
Full TDAX calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — TDAX vs MRK

📍 MRK pulled ahead of the other in Year 2

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTDAXMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TDAX + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TDAX pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TDAX
Annual income on $10K today (after 15% tax)
$437.70/yr
After 10yr DRIP, annual income (after tax)
$608.36/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, MRK beats the other by $7,720.05/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TDAX + MRK for your $10,000?

TDAX: 50%MRK: 50%
100% MRK50/50100% TDAX
Portfolio after 10yr
$42.4K
Annual income
$5,256.93/yr
Blended yield
12.39%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

TDAX
No analyst data
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TDAX buys
0
MRK buys
0
No recent congressional trades found for TDAX or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTDAXMRK
Forward yield5.15%2.76%
Annual dividend / share$1.05$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$28.1K$56.8K
Annual income after 10y$715.72$9,798.13
Total dividends collected$6.2K$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: TDAX vs MRK ($10,000, DRIP)

YearTDAX PortfolioTDAX Income/yrMRK PortfolioMRK Income/yrGap
1$11,215$514.95$11,206$366.19+$9.00TDAX
2← crossover$12,540$539.73$12,650$502.35$110.00MRK
3$13,982$564.00$14,407$694.19$425.00MRK
4$15,548$587.71$16,585$967.82$1.0KMRK
5$17,247$610.80$19,342$1,363.89$2.1KMRK
6$19,088$633.23$22,913$1,947.19$3.8KMRK
7$21,079$654.95$27,662$2,823.89$6.6KMRK
8$23,230$675.96$34,159$4,173.35$10.9KMRK
9$25,552$696.22$43,337$6,308.80$17.8KMRK
10$28,057$715.72$56,776$9,798.13$28.7KMRK

TDAX vs MRK: Complete Analysis 2026

TDAXStock

TDAX seeks to deliver leveraged exposure equal to 130% of the daily performance of TDAQ, with portfolio exposure reset at the close of each trading day. The fund primarily uses swap agreements and, at times, exchange-traded call options to maintain its targeted daily exposure, rebalancing as needed based on market movements. Because exposure is reset daily, returns over periods longer than one trading day reflect the compounding of daily results and can differ materially from TDAQs performance over the same timeframe. The fund pursues its objective regardless of market conditions and does not take defensive positions, which can lead to high portfolio turnover. As a leveraged product, performance is highly sensitive to short-term price movements, and a sufficiently large adverse move in TDAQ during a single trading day could result in a complete loss of value.

Full TDAX Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this TDAX vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TDAX vs SCHDTDAX vs JEPITDAX vs OTDAX vs KOTDAX vs MAINTDAX vs JNJTDAX vs ABBVTDAX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.